What does RPTD stand for?

Recommended Phase II Dose (pharmaceutical research)

This definition appears very rarely and is found in the following Acronym Finder categories:

Science, medicine, engineering, etc.

Other Resources:

<< Previous	Abbreviation Database Surfer		Next >>
Repeatback Rat Proximal Tubular Cell Receiver Plain Text Clock Regional Police Training Centre (Barbados) Rinecker Proton Therapy Center Rock Port Telephone Company (Missouri) Rosa Parks Transit Center (Detroit, MI) Roseville Park Tennis Club (Australia) Regional Power Trade Coordination Committee Directors of Real Property Tax Services		Rencana Pembangunan Tahunan Desa (Indonesian: Annual Village Development Plan) Rent Paid to Date Raddest Photo Trip Ever (travel) Rat Kidney Proximal Tubule Epithelial Cell (biology) Reading Proficiency Tests in English Renal Proximal Tubule Epithelial (cell biology) Renal Proximal Tubule Epithelial Cell (biology) Rabbit Proximal Tubule Epithelial Cell Renal Proximal Tubular Epithelial Cell Research and Practice in Technology Enhanced Learning (journal)

Samples in periodicals archive:

The trial's primary objective is to determine safety, tolerability and recommended Phase II dose, and patients with metastatic solid tumors who are refractory to available therapies or for whom no standard systemic therapy exists will be enrolled.

Clinic Roundup

Sixty-nine adult patients from Spain participated, 15 in the dose escalating part and 54 at the recommended phase II dose.

Sopherion Therapeutics, LLC Announces Publication of Phase I/II ...

The maximum tolerated dose and the recommended Phase II dose have not yet been determined.

Clinical Data on Oncology HDAC Inhibitor MGCD0103 Presented at the ...

The recommended Phase II dose was satraplatin at 40mg/m2/day given on days 1-5 and docetaxel at 60mg/m2 given on day 1 of a three-week cycle, without G-CSF, and satraplatin at 50mg/m2/day given on days 1-5 and docetaxel at 70mg/m2 given on day 1 of a three-week cycle with G-CSF.

New Data from Several Satraplatin Clinical Trials in Solid Tumors ...

The trial objectives are to assess safety and to determine the maximum tolerated dose and dose-limiting toxicity by applying a dose-escalation schedule with a limited number of patients and to define the recommended Phase II dose.

Clinic Roundup

Recommended Phase II Dose of MGCD0103 Determined as 90 mg * 53% of Patients Treated with 90 mg Dose Achieved a Clinical Response * Patients with Responses Experienced a 66% Reduction in the Risk of Death Compared to Non-responders ATLANTA, Dec.

Pharmion and MethylGene Present Favorable Clinical Data From ...

Immediately upon determination of a recommended Phase II dose for IMC-A12 combined with gemcitabine and erlotinib, a Phase II multicenter study will begin.

Phase I/II Studies of IMC-A12 in Pancreatic Cancer Open for Patient ...

The primary objectives are to determine the safety and tolerability of TM601, to determine the target recommended Phase II dose and the biologically active dose of TM601 when administered intravenously and to study the pharmacokinetics of TM601 at each dose level.

Clinic Roundup